SEC Form 4 · accession 0001104659-17-031894
NOVELION THERAPEUTICS INC. · NVLN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Mary T Szela
Officer — Chief Executive Officer · Director
Period of report
May 9, 2017
Accepted (ET)
May 11, 2017 · 4:02 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000827809
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common SharesF1,F2 | May 9, 2017 | M | 6,632 | — | A | 6,632 | D | |
| Common SharesF3 | May 9, 2017 | F | 2,248 | $9.42 | D | 4,384 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Restricted Stock UnitsF1,F2,F4 | — | May 9, 2017 | M | 6,632 | D | — | — | Common Shares | 6,632 | 13,264 | D |
Explanation of responses
- F1Reflects a one-for-five share consolidation of the common shares of the Issuer effective December 16, 2016.
- F2Each restricted stock unit represents a contingent right to receive one common share.
- F3The shares reported as disposed were withheld by the Issuer to satisfy tax withholding obligations of the Reporting Person.
- F433.34% of the grant vested on May 9, 2017. Subject, with limited exceptions, to the Reporting Person's continued employment with the Issuer or one of its affiliates, 33.33% of the grant will vest on May 9, 2018 and 33.33% of the grant will vest on May 9, 2019.